Overview
- Moderna and Merck announced Wednesday that an interim Phase 3 analysis found their personalized mRNA vaccine intismeran plus Keytruda met the trial’s primary endpoint of recurrence‑free survival and a key secondary endpoint of distant metastasis‑free survival.
- The randomized study enrolled about 1,137 patients with completely resected stage IIB–IV melanoma and compared Keytruda plus the bespoke neoantigen vaccine to Keytruda alone.
- The companies have released only topline results and have not published detailed hazard ratios, absolute event rates, subgroup analyses, or peer‑reviewed data and they are still following patients for overall survival.
- Each vaccine dose is made to order from a patient’s tumor profile and typically takes roughly six weeks to manufacture while patients receive Keytruda, raising questions about manufacturing scale, turnaround time, and cost for wide use.
- The announcement sent Moderna and Merck shares sharply higher and the firms plan to present full trial data at a major medical meeting and to engage regulators about potential filings as they test the approach in other cancers.